Testing for specific variants has become standard of care in many cancers (e.g., EGFR analysis in non-small cell lung cancer), but next generation sequencing has enabled the ability to examine hundreds of genes and biomarkers that are implicated in cancer biology. This evidence concerns the gene EGFR and cancer.